Etomidate Induction in Hysteroscopic Surgery

NCT ID: NCT05520645

Last Updated: 2022-08-30

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-25
• Study Completion Date: 2023-12-30

Brief Summary

This study intends to study the optimal dose induced by etomidate in outpatients undergoing painless hysteroscopic surgery. At present, the dosage in the user manual is 0.1-0.3mg/kg. In clinical use, it is found that 0.1mg/kg often fails to achieve sedative effect, and 0.3mg/kg is prone to muscle twitching. Therefore, three groups of doses of 0.15mg/kg, 0.2mg/kg and 0.25mg/kg are set. It is hoped that this study will provide a basis for clinical evaluation of etomidate in anesthesia induction of hysteroscopic surgery.

Conditions

Etomidate Induced Dose; Hysteroscopic Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Eto 0.15mg/kg

Etomidate 0.15mg/kg for anesthesia induction

Group Type: EXPERIMENTAL

etomidate

Intervention Type: DRUG

use etomidate for anesthesia induction in hysteroscopic surgery

Eto 0.2mg/kg

Etomidate 0.2mg/kg for anesthesia induction

Group Type: EXPERIMENTAL

etomidate

Intervention Type: DRUG

use etomidate for anesthesia induction in hysteroscopic surgery

Eto 0.25mg/kg

Etomidate 0.25mg/kg for anesthesia induction

Group Type: EXPERIMENTAL

etomidate

Intervention Type: DRUG

use etomidate for anesthesia induction in hysteroscopic surgery

Propofol 2mg/kg

propofol 2mg/kg for anesthesia induction

Group Type: ACTIVE_COMPARATOR

propofol

Intervention Type: DRUG

use propofol for anesthesia induction in hysteroscopic surgery

Interventions

etomidate

use etomidate for anesthesia induction in hysteroscopic surgery

Intervention Type: DRUG

propofol

use propofol for anesthesia induction in hysteroscopic surgery

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients to undergo hysteroscopic surgery

Exclusion Criteria

Hemo-dynamically unstable patients Allergic to egg protein Patients with epilepsy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

89476

Identifier Type: -

Identifier Source: org_study_id